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Abstract 
Epilepsy affects about 50 million people worldwide. Sudden unexpected death in epilepsy 
(SUDEP) is the main cause of death in epilepsy accounting for up to 17% of all deaths in 
epileptic patients, and therefore remains a major public health problem. SUDEP likely arises 
from a combination and interaction of multiple risk factors (such as being male, drug 
resistance, frequent generalized tonic-clonic seizures) making risk prediction and mitigation 
challenging. While there is a general understanding of the physiopathology of SUDEP, 
mechanistic hypotheses linking risk factors with a risk of SUDEP are still lacking. Identifying 
cross-talk between biological systems implicated in SUDEP may facilitate the development of 
improved models for SUDEP risk assessment, treatment and clinical management. In this 
review, the  aim was to explore an overlap between the pathophysiology of hypertension, 
cardiovascular disease and epilepsy, and discuss its implication for SUDEP. Presented herein, 
evidence in literature in support of a cross-talk between the renin–angiotensin system (RAS) 
and sympathetic nervous system (SNS), both known to be involved in the development of 
hypertension and cardiovascular disease, and as one of the underlying mechanisms of 
SUDEP. This article also provides a brief description of local RAS in brain 
neuroinflammation and the role of centrally acting RAS inhibitors in epileptic seizure 
alleviation. 





Epilepsy with its comorbidities such as depression and anxiety significantly affect 
quality of life. Importantly, mortality rates in epileptics are greatly higher than that of the 
general population [1], and sudden unexpected death in epilepsy (SUDEP), known as a 
seizure related event, is the main cause of death in those patients. The etiology of SUDEP 
remains unclear. Effective seizure control was shown to be a preventive strategy for 
premature death in epilepsy [2], however, approximately 30% of patients do not respond to 
treatment with common anticonvulsants [3]. 
Epileptic seizures result from uncontrollable neuronal excitation in the brain; 
therefore, epilepsy is considered to be a neuronal disease. However, recent investigations 
indicate that the model of epileptogenesis could be more complex. The evidence that seizure 
increases levels of inflammatory mediators in brain suggests that cytokines and 
prostaglandins could be therapeutic targets for new antiepileptic drugs [4]. Experimental 
studies on animal models of epilepsy showed that local renin–angiotensin system (RAS) in 
the brain is involved in neuroinflammation and administration of common antihypertensive 
drugs, such as angiotensin II receptor blocker (ARB) that crosses the brain barrier, reduces 
blood pressure and attenuated neuronal injury [3, 5].  
In the current literature a few review papers targeting the possible pathophysiology 
mechanism of SUDEP, but no one has confronted hypertension with epilepsy. Some 
interesting original articles present studies conducted on animal models with hypertension and 
epilepsy, suggesting the overlap between hypertension and epilepsy pathophysiology. 
The aim of this review is to present pathophysiological and clinical aspects of 
hypertension, cardiovascular diseases (CVD) and epilepsy and to explore the possibility that 
these disorders are related to each other. 
This review advances the hypothesis that components of RAS in association with 
sympathetic activity may play a crucial role in the patomechanism of SUDEP.       Evidence in 
the literature is presented that shows RAS inhibitors may be used to potentially  alleviate 
epileptic seizures and build a hypothesis that targeting RAS may also reduce the risk of 
SUDEP. 
 
Epilepsy and SUDEP 
Epilepsy is a neurological disease characterized by recurrent seizures resulting from 
abnormal excessive or synchronous activity in brain [6]. An imbalance between excitation 
and inhibition in the brain, the basis of this phenomenon, results from alterations at many 
levels of brain functioning, neuronal circuits, and genetic predisposition [7]. Epilepsy 
diagnosis requires the presence of at least one unprovoked seizure in a patient who has other 
factors associated with high recurrence risk of latter seizures [1, 6]. Depending on the 
character of the onset, seizures are classified as focal or generalized, with motor or nonmotor 
onset [8]. Status epilepticus (SE) is defined as 5 min of ongoing seizure activity to diagnose 
convulsive SE (bilateral tonic-clonic SE) and 10 min for focal or absence SE [9]. 
Every hundredth person suffers from epilepsy and in about one-third of those patients, 
refractory epilepsy is recognized [7]. Importantly, the risk of premature death in patients with 
epilepsy is about 2–3 times higher than the general population [1]. 
SUDEP accounts for up to 17% of deaths in patients with epilepsy [10]. SUDEP is 
defined as a sudden, unexpected, witnessed or unwitnessed, non-traumatic and non-drowning 
death in patients with epilepsy, with or without evidence of a seizure excluding documented 
status epilepticus, in which postmortem examination does not reveal a toxicological or 
anatomical cause of death [11]. SUDEP incidence is estimated to be from 0.3 to 6 persons per 
1000 adult person-years [2]; however, SUDEP may be under-diagnosed due to the fact that 
the 10th revision of International Classification of Disease does not include term SUDEP as a 
cause of death [1, 10]. 
There are still limited tools to stratify individual risk for SUDEP [12]. A number of 
risk factors have been reported to be associated with SUDEP, including general tonic-clonic 
seizures and poor seizure control, young onset and long duration of epilepsy, and young age 
[11]. It is estimated that young adults (aged 20–45 years) have 27.5 higher risk of SUDEP 
than the general population [13]. The reasons for the increased incidence of SUDEP in early 
adulthood are unknown, therefore a better understanding of underlying pathophysiology is 
crucial for treatment and SUDEP prevention [10]. 
 
Pathomechanism of SUDEP: Sympathetic system and heart. 
Sudden unexpected death in epilepsy is proposed to result from the accumulation of 
disturbances in numerous biological systems such as the cardiac, respiratory, and nervous 
systems [11]. MORTEMUS study suggested that impaired respiratory function may play a 
crucial role in this condition based on the fact that terminal apnea always preluded terminal 
asystole in epileptic patients who died unexpectedly [14]. In addition, the brainstem arousal 
system dysfunction and dysregulation in the neurotransmitter and neuromodulator system are 
mechanisms that presumably take part in the pathogenesis of SUDEP [12].  
Seizure affects cardiac function which may lead to Takotsubo syndrome, 
cardiomyocyte injury, arterial hypertension and probably even premature death in epileptic 
patients [15]. Clinical data suggest that there is a resemblance between SUDEP and sudden 
cardiac deaths such as both unexpected events are characterized by abrupt loss of 
consciousness [16]. Sudden cardiac deaths occur mostly in the morning when the patient is 
awake, while SUDEP mostly when patient is asleep in a prone position [12]. Ruthirago at al. 
[10] suggested that some cases of SUDEP could be misinterpreted as sudden cardiac deaths, 
cardiorespiratory failure or sudden infant death syndrome, especially in patients without prior 
diagnosis of epilepsy. 
Seizures affect central autonomic system and as a result may alter pulmonary and 
cardiovascular functions which are linked with the risk of SUDEP [17]. Refractory epilepsy is 
accompanied by increased sympathetic tone and reactivity and decreased parasympathetic 
tone and reactivity [15]. More than 90% cases of seizure are associated with increased heart 
rate, suggesting that cardiac dysfunction is strongly related to chronic, refractory epilepsy 
[18]. According to Powell et al. [19], chronic epilepsy contributes to channelopathy, that can 
result in fatal arrhythmias. Electrocardiographic abnormalities, including repolarization 
alteration, are found in individuals with a long history of epilepsy. ST segment depression 
was described to occur during and just after the seizure. QT lengthening was also observed in 
an association with electroencephalographic discharges, especially in those patients who have 
later died from SUDEP [20].  
Importantly, anticonvulsants may also trigger SUDEP by facilitating the occurrence of 
severe cardiac arrhythmias via altering cardiac conduction and the length of QT interval. 
Interestingly, an abrupt antiepileptic drugs withdrawal results in increased sympathetic tone 
and therefore could create conditions for sudden, unexpected death [3, 11, 21]. 
 
Prevalence of hypertension with the focus on young population 
Hypertension affects 30–45% adults worldwide [22]. The incidence of arterial 
hypertension is projected to increase by 15–20% by 2025 as a consequence of an aging 
population and the obesity epidemic [22].  
The prevalence of hypertension in a group of adults aged 18–39 is 7.3%, the majority 
are men. This group of patients is less likely to have controlled hypertension than those aged 
60 and over [23]. Clinical data demonstrated that young adults with documented elevated 
blood pressure have slower rates of antihypertensive medication initiation than older patients. 
Importantly, uncontrolled hypertension, both in young and older populations, increases the 
risk of future cardiovascular events [24]. 
 
Hypertension mediated organ damage: The role of RAS and sympathetic system 
Untreated or poorly controlled hypertension is associated with structural and/or 
functional changes in heart, blood vessels, brain, eyes and kidneys, which are markers of 
asymptomatic CVD [22]. The role of systemic RAS is classically recognized in the regulation 
of cardiovascular homeostasis. RAS plays a critical role in the pathophysiology of 
hypertension, and therefore in the development of hypertension-related target organ damage 
[25]. A growing body of evidence shows that circulating RAS does not act independently, but 
in cooperation with local RAS in different tissues and organs [26]. The extent of local RAS 
contribution to cardiovascular complications remains unknown [26]. 
The activated RAS is associated with the altered expression and distribution of its 
components, with the main focus on angiotensin II (Ang II) and its receptor angiotensin II 
type 1 receptor (AT1), the strongest element of RAS [26]. Overactivity of AT1 receptor has 
been demonstrated to be associated with vascular remodeling, endothelial dysfunction and 
accelerated arterial stiffening [27]. Conversely, angiotensin-converting enzyme inhibitors 
(ACEI) and AT1 receptor blockers have been shown to prevent tissue damage. Conceivably, 
the beneficial effect of ACEI and AT1 receptors may be attributed to both systemic and local 
RAS blockage/inhibition [25].  
An overactive sympathetic nervous system (SNS) is characteristic for CVD including 
hypertension and hypertension-related organ damage, such as left ventricular hypertrophy, 
renal dysfunction or arteriolar remodeling. [28]. Many studies suggest that the RAS might be 
a link between sympathetic nervous system activity and hypertension [29]. 
It has been shown that SNS affects the release of renin from the kidneys. Ang II, a 
crucial effector of RAS which acts by binding to AT1 receptors on sympathetic nerve 
endings, induces SNS activity by enhancing norepinephrine release [26]. Taken altogether, it 
suggests that inhibition of RAS contributes to decreased SNS activity and alleviated organ 
complications. 
 
Hypertension and epilepsy 
According to the study presented by Wilner et al. [30], on a group of patients older 
than 19 years with epilepsy , hypertension was the most common comorbid condition. This 
observation suggests that hypertension may play an important role in epilepsy. 
The association between hypertension and epilepsy seems to be bidirectional. The 
cerebral damage resulting from high blood pressure could lower seizure threshold and 
therefore cause epilepsy [31]. Thus, chronic hypertension contributes to late onset of seizure 
[32]. On the other hand, seizure onset is connected with increased sympathetic tone. That 
could lead by itself to increased blood pressure. Hypertension as a frequent, sometimes severe 
comorbid condition, and may be complicated by posterior reversible encephalopathy 
syndrome in some cases [20].  
 
Brain RAS and neuroinflammation 
The brain RAS is involved in body water balance, maintenance of blood pressure, 
cyclicity of reproductive hormones and sexual behaviors, and regulation of releasing pituitary 
gland hormones [33]. A growing body of evidence suggests the role of neuroinflammation in 
the pathology of epilepsy, as it has been shown, is the association with the occurrence of 
seizure and generation of pathological lesions after seizure [34]. According to Sun et al. [5], 
the expression of Ang II peptide substantially increased in activated microglia after seizure. 
Ang II and its AT1 receptor amplify neuroinflammatory reaction, that in turn contribute to 
neurodegeneration. Subsequently, the inhibition of AT1 receptor may result in reduced 
inflammatory response and decreased levels of oxidative stress. In epilepsy RAS inhibitors 
may act as anti-inflammatory and neuroprotective agents. Experimental studies have also 
shown that blockade of AT1 receptor reduced the infarct volume after ischemia in rats. The 
neuroinflammation in the hippocampus is strongly associated with activated microglia and 
cognitive impairment in epileptic patients [5, 35, 36]. Interestingly, it has been reported that 
ACEI can attenuate neuroinflammation and prevent neuronal loss in the hippocampus during 
epilepsy [37]. Contrary to Ang II, the axis Ang 1-7/Mas receptor is involved in attenuation of 
the inflammatory process.  Anti-inflammatory action can also exist in the brain and may play 
an important role in epilepsy [38].  
 
RAS inhibitors alleviate epileptic seizure 
Hippocampus is recruited in the most common type of epilepsy — temporal lobe 
epilepsy [34]. Rat epilepsy models showed that seizures were associated with increased 
expression of ACE and AT1 receptor in the temporal lobe epilepsy. In turn, treatment with 
ACEI substantially reduced limbic and tonic-clonic seizure severity without affecting blood 
pressure [3, 31, 39]. ARB treatment was associated with not only seizure suppression, but also 
systolic blood pressure reduction [3].  
Other studies have revealed that pilocarpine-induced acute and silent phase of 
experimental status epilepticus was associated with a high concentration of Ang 1-7 peptides. 
This observation was attributed to the response to injury and the anti-inflammatory effects of 
Ang 1-7. The chronic period (which started with the first spontaneous seizure, after the acute 
and silent phase) was associated with higher levels of Ang II peptides contrary to the acute 
and silent phase, which was accompanied with its lower concentrations. The expression of 
tonin mRNA, element of local RAS, an alternative pathway to Ang II generation from 
angiotensinogen, were significantly increased [40].  
ARBs have been shown to affect transforming growth factor (TGF)-beta signaling 
pathway. This cytokine is associated with vascular injury in the brain e.g. after stroke and 
trauma, and thus may play a crucial role in epileptogenesis. Losartan effectively blocked 
TGF-beta activation in the brain and in this way acted as antiepileptic drug in the animal 
model of acquired epilepsy [39]. The potential neuroprotective effects of RAS targeted drugs 
were demonstrated by a study showing that administration of losartan (ARB) led to essential 
delays in the occurrence of seizure, shorten seizure duration and frequency in the animal 




A better understanding of SUDEP is needed to develop effective prevention strategies. 
In this review, compelling evidence is presented describing the link between hypertension, 
brain RAS, sympathetic system and epilepsy. Based on evidence from literature it is 
hypothesized that targeting RAS may be an effective strategy to reduce epileptic seizure in 
humans and potentially reduce the risk of SUDEP.  
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